致源禾谷和诺禾禾谷的普通合伙人、执行事务合伙人均为公司控股股东、实控人李瑞强。 人民财讯3月19日电，诺禾致源(688315)3月19日晚间公告，公司股东致源禾谷、诺禾禾谷合计持有公司 14.34%股份，计划通过集中竞价、大宗交易方式减持公司股份合计不超1248.6万股，占公司总股份的 3%。 ...

Investment Rating - The industry investment rating is "Recommended" [1] Core Viewpoints - The report highlights a revolution in sequencing technology empowered by AI, with domestic companies accelerating their AI business layout [5][6] - The domestic sequencing market is rapidly growing, with China becoming the second-largest gene testing market globally, surpassing 33.5 billion RMB in 2024 [31] - AI technology is significantly reducing costs and enhancing the efficiency and accuracy of sequencing processes, leading to advancements in personalized treatment and drug development [32] Summary by Sections Industry Overview - The pharmaceutical and biotechnology industry includes 645 listed companies with a total share capital of 5,825.23 million shares and sales revenue of 37,462.19 billion RMB [1] - The total profit for the industry is 3,382.22 billion RMB, with an average PE ratio of 42.37 [1] Market Performance - The pharmaceutical index increased by 1.06% during the week of March 3-7, 2025, underperforming the CSI 300 index, which rose by 1.39% [7][9] - The pharmaceutical industry index PE (TTM, excluding negative values) is 26.65 times, with a valuation premium of 121.81% compared to the CSI 300 index, indicating a historical low [9] AI Empowerment in Sequencing Technology - AI is optimizing sequencing processes and data analysis algorithms, enhancing speed and accuracy [31] - Domestic companies like BGI and Tempus are leveraging AI to create closed-loop ecosystems for data analysis and clinical applications [20][21] - The report emphasizes the importance of AI in reducing detection costs and improving personalized treatment options [32] Key Companies and Developments - Tempus AI focuses on integrating AI with clinical diagnostics, utilizing a vast database for drug development and clinical trial optimization [20][21] - BGI is enhancing sequencing efficiency through AI tools and has established a significant presence in over 100 countries [32] - Other notable companies include Shengxiang Biology, Novogene, and Berry Genomics, all of which are advancing their AI capabilities in sequencing and diagnostics [34][35]

Investment Rating - The report assigns an investment rating of "Recommended" for the pharmaceutical and biotechnology industry [3][33]. Core Insights - The "AI + Healthcare/Pharmaceutical" theme continues to gain traction, with short-term momentum expected to persist. The report highlights significant stock performance in the sector, with the pharmaceutical and biotechnology sector (SW) rising by 2.71%, outperforming the CSI 300 index, and all sub-sectors showing positive growth, particularly in medical services [3][4]. - In the U.S., Tempus AI, a representative company in medical AI, saw a weekly increase of approximately 30% and over 160% year-to-date, driving the momentum of the medical AI concept. In China, companies like KingMed Diagnostics and Dian Diagnostics announced collaborations with DeepSeek, indicating a shift towards the commercialization of AI applications in healthcare [4][3]. - The report emphasizes investment opportunities in sub-sectors such as "AI + Medical Imaging," "AI + Diagnostic Services," and "AI + Drug Development," recommending key companies including United Imaging, Mindray, BGI Genomics, and WuXi AppTec [3][4]. Industry Performance Tracking - The pharmaceutical and biotechnology sector (SW) rose by 2.71% in the week of February 10-14, ranking 5th among 31 Shenwan primary industries. The CSI 300 index increased by 1.19% during the same period [5][6]. - All sub-sectors experienced growth, with medical services leading at +6.51%, followed by medical devices at +4.81%, and pharmaceutical commerce at +4.18% [5][6]. - Notable individual stock performances included Dian Diagnostics (+46.29%), Mian Health (+31.58%), and United Imaging (+27.33%) [6]. Industry Dynamics and Key Company Tracking - The National Healthcare Security Administration released a list of key tasks for 2025, focusing on efficient medical insurance processes and direct settlements for collected drugs and consumables [7]. - The retail terminal drug sales scale in China is projected to reach 574 billion yuan in 2024, with a growth rate of 3.7%, indicating a slowdown in growth due to demographic and economic factors [8]. - The report also notes significant collaborations, such as Baiyang Pharmaceutical's agreement with Roche for the exclusive marketing rights of a targeted cancer drug in mainland China [9][11]. Industry Data Tracking - The report tracks various industry metrics, including the basic medical insurance fund income, which reached 28,507.29 billion yuan in 2024, showing a year-on-year growth of 5% [15][16]. - The domestic pharmaceutical manufacturing industry achieved a total revenue of 25,298.50 billion yuan in 2024, with profit totals declining by 1.1% year-on-year [17].

Financial Performance - Total operating revenue for 2024 reached RMB 2,111.32 million, a year-on-year increase of 5.45%[3] - Net profit attributable to shareholders of the parent company was RMB 1,944.48 million, reflecting a growth of 9.20% compared to the previous year[3] - Net profit attributable to shareholders of the parent company after deducting non-recurring gains and losses was RMB 1,672.88 million, up 19.50% year-on-year[3] - Basic earnings per share rose to RMB 0.48, a 9.09% increase from the previous year[3] - The weighted average return on net assets decreased to 7.93%, down 0.55 percentage points from the previous year[3] Assets and Equity - Total assets at the end of the reporting period amounted to RMB 36,366.04 million, an increase of 1.17% from the end of 2023[6] - Shareholders' equity attributable to the parent company was RMB 24,889.76 million, growing by 1.28% compared to the end of 2023[6] Strategic Initiatives - The company emphasized a strategy of total cost leadership and expanded overseas market presence to boost revenue[6] - Increased investment in new product and technology development to enhance innovation capabilities[6] Profitability Metrics - The company reported improvements in gross margin and profit margin, indicating enhanced profitability metrics[6]

好的，非常感谢今天来参会的投资人。今天也是我们山西证券医药春季上市公司交流的系 列电话会之一。今天我们非常荣幸的邀请到了诺禾致源的证券事务代表赵丽华赵总。我是 山西证券的医药研究员任新平，我主要覆盖医疗器械还有医疗服务领域。今天之所以想和 大家聊一下诺和资源这家公司，也是因为最近这个 AI 家的相关话题非常火。我们通过前面 的一些研究也发现，诺禾致源是一家基本面很好啊，而且在基因测序领域也算是一个小龙 头的企业。 首先希望赵总给我们简单介绍一下公司近期的经营情况，因为其实 24 年三季报已经发了， 那大家可能会对于 24 年四季度，还有 25 年最近以及 25 全年的业绩展望想做更多的了解， 谢谢赵总。 各位投资人大家好，诺和之源、赵丽华，最近明显感觉大家这个市场情绪还是比较比较热 烈的。我这边就是做了最近近一年投，我从去年能够感觉到大家市场上还是信心摇摆到现 在也能够在更多的交流中，能够感受到大家这波 AI 带来的热情。然后我先简单介绍一下公 司最近的一些情况。因为现在是 2 月 24 号，然后基本上也是快到了寒假的这样的一个尾 声阶段。我们其实在每年的一季度，如果说大家跟公司比较久的话，其实公司还是有一个 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 北京诺禾致源科技股份有限公司（以下简称"公司"）股票于 2025 年 2 月 14 日、2025 年 2 月 17 日连续两个交易日内日收盘价格涨幅偏离值累计超过 30%，根据《上海证券交易所科创板股票异常交易实时监控细则》的有关规定， 已构成股票交易异常波动情形。 经公司自查，并向控股股东及实际控制人核实，截至本公告披露日，不 存在应披露而未披露的重大信息。 证券代码：688315 证券简称：诺禾致源 公告编号：2025-004 北京诺禾致源科技股份有限公司 股票交易异常波动公告 一、股票交易异常波动的具体情况 本公司股票于 2025 年 2 月 14 日、2025 年 2 月 17 日连续两个交易日内日收 盘价格涨幅偏离值累计超过 30%，根据《上海证券交易所科创板股票异常交易实 时监控细则》的有关规定，已构成股票交易异常波动情形。 二、公司关注并核实的相关情况 根据上海证券交易所相关规定，公司对相关问题进行了必要核实。现说明如 下： 1、经公司自查，公司 ...

《关于北京诺禾致源科技股份有限公司股票交易异常波动 的询证函》的回函 致： 北京诺禾致源科技股份有限公司 贵公司《关于北京诺禾致源科技股份有限公司股票交易异常波动的询证函》 己收悉， 现就公司询证事项回复如下： 1、截至目前， 作为贵公司控股股东、 实际控制人， 不存在正在筹划并购重 组、股份发行、债务重组、业务重组、资产剥离和资产注入等重大事项， 亦不存 在其他应披露而未披露的重大信息。 2、本人及一致行动人在贵公司本次股票异常波动期间， 不存在买卖贵公司 股票的情况。 （本页以下无正文） (本页无正文,为《<关于北京诺禾致源科技股份有限公司股票交易异常波 动的询证函>的回函》之签署页。） 控股股东及实际控制人: 20达年 2月 ...

证券代码：688315 证券简称：诺禾致源 公告编号：2025-003 北京诺禾致源科技股份有限公司 关于以集中竞价交易方式回购公司股份实施结果 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 二、 回购实施情况 1、2024 年 2 月 28 日，公司通过上海证券交易所交易系统以集中竞价交易方 式首次回购公司股份 50,000 股，占公司总股本的比例为 0.012%，具体内容详见公 司于 2024 年 2 月 29 日在上海证券交易所网站（www.sse.com.cn）披露的《北京诺 禾致源科技股份有限公司关于以集中竞价交易方式首次回购公司股份的公告》（公 告编号：2024-007）。 2、截至本公告披露日，公司本次股份回购方案已实施完毕。公司通过上海证 券交易所交易系统以集中竞价交易方式已累计回购公司股份 11,141,468 股，占公 司总股本的比例为 2.68%，回购成交的最高价为 15.86 元/股，最低价为 9.69 元/股， 回购均价为 12.94 元/股，支付的资金总额为人民币 14 ...

关于以集中竞价交易方式回购公司股份的进展公告 证券代码：688315 证券简称：诺禾致源 公告编号：2024-052 北京诺禾致源科技股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/2/6，由实际控制人、董事长兼总经理李瑞 强提议 | | | --- | --- | --- | | 回购方案实施期限 | 年 2 月 5 日第三届董事会第十五次会议审 | 2024 | | | 议通过后 12 个月 | | | 预计回购金额 | 8,000 万元~16,000 万元 | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | □用于转换公司可转债 | | | | □为维护公司价值及股东权益 | | | 累计已回购股数 | 1,114.15 万股 | | | 累计已回购股数占总股本比例 | 2.68% | | | 累计已回购金额 | 14,414.75 万元 | | | 实际回购价格区间 | 元/股~15.86 元/股 | 9.69 ...

证券代码：688315 证券简称：诺禾致源 公告编号：2024-051 北京诺禾致源科技股份有限公司 关于召开 2024 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2024 年 11 月 29 日(星期五)下午 13:00-14:00 会 议 召 开 地 点 ： 上海证券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2024 年 11 月 22 日(星期五)至 11 月 28 日(星期四)16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@novogene.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回 答。 北京诺禾致源科技股份有限公司（以下简称"公司"）已于 2024 年 10 月 25 日发布公司 2024 年第三季度报告，为便于广大投资者更全面深入地了解公司 2024 年第三季度经营成果、 ...